Stockscreener 앱 받기
0.79
2.35%
-0.019
전일 마감가:
$0.809
열려 있는:
$0.8187
하루 거래량:
3,437
Relative Volume:
0.04
시가총액:
$25.11M
수익:
$8.59M
순이익/손실:
$-17.07M
주가수익비율:
-1.2951
EPS:
-0.61
순현금흐름:
$-21.90M
1주 성능:
+3.22%
1개월 성능:
+2.73%
6개월 성능:
-47.68%
1년 성능:
-42.34%
1일 변동 폭
$0.79
$0.8187
1주일 범위
$0.73
$0.8652
52주 변동 폭
$0.701
$1.88
Durect Corp Stock (DRRX) Company Profile
명칭
Durect Corp
전화
(408) 777-1417
주소
10240 BUBB ROAD, CUPERTINO, CA
DRRX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
DRRX
Durect Corp
|
0.79 | 25.11M | 8.59M | -17.07M | -21.90M | -0.61 |
|
ZTS
Zoetis Inc
|
159.64 | 71.40B | 9.26B | 2.49B | 2.30B | 5.47 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.03 | 47.36B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
HLN
Haleon Plc Adr
|
10.15 | 46.03B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.41 | 18.86B | 16.54B | -1.64B | 749.00M | -1.45 |
|
ITCI
Intra Cellular Therapies Inc
|
131.26 | 13.96B | 612.78M | -86.37M | -62.91M | -0.87 |
Durect Corp Stock (DRRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2020-10-30 | 개시 | Chardan Capital Markets | Buy |
| 2020-10-12 | 개시 | ROTH Capital | Buy |
| 2020-07-31 | 개시 | Oppenheimer | Outperform |
| 2020-01-31 | 개시 | B. Riley FBR | Buy |
| 2019-11-18 | 재개 | Cantor Fitzgerald | Overweight |
| 2019-09-06 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-03-06 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2017-10-20 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2017-10-20 | 재확인 | Laidlaw | Buy |
| 2017-10-20 | 다운그레이드 | Stifel | Buy → Hold |
| 2017-07-12 | 업그레이드 | Stifel | Hold → Buy |
| 2017-02-28 | 재개 | H.C. Wainwright | Buy |
| 2016-04-25 | 개시 | Rodman & Renshaw | Buy |
| 2015-05-01 | 재확인 | Cantor Fitzgerald | Buy |
| 2015-05-01 | 재확인 | Stifel | Buy |
| 2013-03-25 | 개시 | Stifel | Buy |
| 2012-11-01 | 다운그레이드 | C.K. Cooper | Buy → Hold |
| 2012-08-17 | 개시 | C.K. Cooper | Buy |
| 2009-06-23 | 개시 | Caris & Company | Buy |
| 2009-03-26 | 개시 | Wedbush Morgan | Hold |
모두보기
Durect Corp 주식(DRRX)의 최신 뉴스
Wnt efforts condensing at Dewpoint, Surrozen, more - BioWorld Online
Larsucosterol flops on clinical benefit in phase 2b alcohol-associated hepatitis trial - Healio
DURECT (NASDAQ:DRRX) Earns Sell Rating from Analysts at StockNews.com - Defense World
The R&D Dept.: Local patent roundup for 2.26.25 - RichmondBizSense
DURECT (NASDAQ:DRRX) Coverage Initiated at StockNews.com - Defense World
DURECT (NASDAQ:DRRX) Research Coverage Started at StockNews.com - Defense World
DURECT Corporation to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference - Yahoo Finance
StockNews.com Initiates Coverage on DURECT (NASDAQ:DRRX) - Defense World
DURECT Corporation Announces Publication of Larsucosterol Phase 2b Results in NEJM Evidence - Stockhouse Publishing
DURECT (NASDAQ:DRRX) Coverage Initiated by Analysts at StockNews.com - Defense World
Durect (DRRX) Upgraded to Strong Buy: Here's Why - Yahoo Finance
Geode Capital Management LLC Has $429,000 Holdings in DURECT Co. (NASDAQ:DRRX) - Defense World
DURECT faces Nasdaq delisting over share price - Investing.com
New Strong Buy Stocks for January 9th - Yahoo Finance
Reviewing Acerus Pharmaceuticals (OTCMKTS:TRLPF) and DURECT (NASDAQ:DRRX) - Defense World
Microbial Products Market Size to Hit USD 351.42 Bn by 2034 - Precedence Research
Durect (DRRX) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
DURECT Corp expected to post a loss of 17 cents a shareEarnings Preview - XM
Is BellRing Brands (BRBR) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
DURECT Corp sells ALZET product line to Lafayette - TradingPedia
Durect announces sale of Alzet line of osmotic pumps to LIC for $17.5M - TipRanks
DURECT Corporation Announces Sale of ALZET® Product Line to Lafayette Instrument Co. for $17.5 Million - PR Newswire
DURECT Corporation (NASDAQ:DRRX) Q3 2024 Earnings Call Transcript - Insider Monkey
Earnings call: DURECT Corporation reports Q3 2024 financials - Investing.com
Durect Corp (DRRX) Q3 2024 Earnings Call Highlights: Revenue Gro - GuruFocus.com
Durect Corp (DRRX) Q3 2024 Earnings Call Highlights: Revenue Growth Amid Cost Reductions and ... - Yahoo Finance
Durect Corp (DRRX) Q3 2024 Earnings Call Highlights: Revenue Growth Amid Cost Reductions and ... By GuruFocus - Investing.com Canada
Durect: Q3 Earnings Snapshot - Houston Chronicle
Durect Corp Q3 2024 Earnings: GAAP EPS of -$0.14 Misses Estimates, Revenue at $1.9 Million Below Expectations - GuruFocus.com
Durect (DRRX) Reports Q3 Loss, Misses Revenue Estimates - Yahoo Finance
Durect reports Q3 EPS (14c), consensus (17c) - TipRanks
DURECT Q3: $4.3M Loss, Plans Phase 3 Trial Amid Funding Needs & License Agreement End | DRRX Stock News - StockTitan
DURECT Corporation Reports Third Quarter 2024 Financial Results and Provides Business Update - PR Newswire
DURECT Corporation to Announce Third Quarter 2024 Financial Results and Provide a Business Update - StockTitan
Scrip Asks…What Does 2023 Hold For Biopharma? Part 5: Technological Advances - Citeline News & Insights
DRRXDurect Corp Latest Stock News & Market Updates - StockTitan
DURECT Corporation to Present Data on Larsucosterol at The Liver Meeting 2024 - StockTitan
Durect Corp (DRRX) Q2 2024 Earnings Call Highlights: Revenue Gro - GuruFocus.com
Durect Corp (DRRX) Q2 2024 Earnings Call Highlights: Revenue Growth and Strategic Advances Amid ... - Yahoo Finance
Durect Corp Annual Meeting Decisions and Shareholder Votes - TipRanks
H.C. Wainwright maintains Neutral rating on Durect shares post FDA meeting - Investing.com
DURECT Corporation Announces Phase 3 Registrational Trial Design for Larsucosterol in Alcohol-associated Hepatitis - PR Newswire
BAT NE turnover rate (A), BAT temperature (B), representative BAT... - ResearchGate
DURECT Corporation to Present at the H.C. Wainwright Global Investment Conference - PR Newswire
DURECT Corporation Reports Second Quarter 2024 Financial Results and Business Update - PR Newswire
DURECT Corporation to Announce Second Quarter 2024 Financial Results and Provide a Business Update - Yahoo Finance
Traditional bioplastic packaging technologies forecast to show decline in market share to 2020 - http://www.plastemart.com/
Durect - The Pharma Letter
DURECT Corporation Receives FDA Breakthrough Therapy Designation for Larsucosterol in Alcohol-Associated Hepatitis - PR Newswire
DURECT Corporation (NASDAQ:DRRX) Q1 2024 Earnings Call Transcript - Insider Monkey
Durect Corp (DRRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.16%
0.86%
자본화:
|
볼륨(24시간):